Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

This study includes pediatric patients with history of either primary or iatrogenic
immune-suppression who are seeking treatment of warts that have already proven recalcitrant
to standard therapy. The first cohort will include 4 patients ages 12 to 17. After all tests
indicate treatment safety, the second cohort will be recruited and will include patients
ages 8 to 17.

Inclusion Criteria:

- 1. The first cohort will include a total of 4 patients ages 12 to 17. After all tests
indicate treatment safety, the second cohort will be recruited and will include
patients ages 8 to 17.Patient is in immune-suppressed status by one of the following:

1. Primary immunodeficiency, which may include but is not limited to the following:

1. Chronic Granulomatous Disease (CGD)

2. Common Variable Immunodeficiency (CVID)

3. DiGeorge Syndrome (DGS)

4. Selective IgA Deficiency

5. Severe Combined Immunodeficiency (SCID)

6. X-Linked Agammaglobulinemia (XLA)

2. Pharmacologic immune-suppressed status from medications including but not
limited to:

1. prednisone

2. cyclosporine

3. azathioprine

4. tacrolimus/ FK506

5. mycophenolate mofetil

6. sirolimus

2. Patient has history of clinically-significant warts that are either
refractory to standard therapy or for which standard therapy is contra-indicated
or unreasonable 3. Patient has a total wart burden of at least 1cm 4. Patients
must have tried and failed at least 2 other conventional treatments for
cutaneous warts, including but not limited to:

- cryotherapy

- topical salicylic acid

- imiquimod

- topical 5FU

- pulsed dye laser therapy

- sinecatechins

- tretinoin or other topical retinoid

- intralesional candida injection

- bleomycin

- electrocautery

- topical cidofovir cream or gel

There will be a one month washout period for all treatment modalities, with the
exception of intralesional candida, which will be 3 months.

5. Patient desires ongoing treatment of their warts 6. Patient and/or their
parent/guardian consents to participating in this study

Exclusion Criteria:

1. Treatment area is either ulcerated, secondarily infected, or significantly
inflamed

2. Treatment area is on face or groin area

3. Patient is pregnant, attempting to become pregnant, or lactating

4. Patient reports active kidney disease, or chart review reveals recent serum
creatinine ≥1.5mg/dL or a history of renal disease/insufficiency or history of
diabetes

5. Patient is currently receiving a nephrotoxic medication

6. Patient has history of hypersensitivity to cidofovir

7. Patient is severely ill and/or hospitalized

8. Patient is receiving chemotherapy